1.
Jewett A. First in Human Clinical Study Demonstrating the Safety and Efficacy of NK101 (supercharged NK cells) in the Treatment of Patients with Cancer. SEE J Immunol [Internet]. 2025 Mar. 25 [cited 2026 Nov. 17];8(CITIM):040. Available from: https://seejim.eu/index.php/seejim/article/view/6102